S-腺苷甲硫氨酸对甲苯磺酸盐 | 71914-80-2

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甲硫氨酸类衍生物
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 中文名称: S-腺苷甲硫氨酸对甲苯磺酸盐
• 中文别名: S-腺甙甲硫氨酸对甲苯磺酸盐
• 英文名称: [(3S)-3-amino-3-carboxypropyl]-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-(4-methylphenyl)sulfonyloxyoxolan-2-yl]methyl]-methylsulfanium
• CAS: 71914-80-2
• 化学式: C22H29N6O7S2+
• 分子量: 553.6
• InChiKey: RFCNTHQSTXQCEP-TVQIYZFXSA-O

物化性质

• 溶解度：
  H2O：0.1 g/mL，澄清

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  37
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  215
• 氢给体数：
  4
• 氢受体数：
  12

安全信息

• WGK Germany：
  3

制备方法与用途

生物活性

S-腺苷-L-甲硫氨酸tosylate（S-腺苷甲硫氨酸tosylate）是由蛋氨酸腺苷转移酶催化，由蛋氨酸和ATP内源性生成的一种重要口服甲基供体。这种物质具有有效的抗抑郁和镇痛作用，可用作膳食补充剂，并且在肝病和骨关节炎的研究中也有所应用。

体外研究

S-腺苷-L-甲硫氨酸（腺苷蛋氨酸）参与三大主要代谢途径：1) 甲基化，作为体内主要的甲基供源；2) 转硫化作用，生成S-腺苷同型半胱氨酸 (SAH)，进而转化为同型半胱氨酸 (Hcy)，后者可以转化为胱硫胺和半胱氨酸，并将硫酸根（SO4）捐赠给其他代谢中间体；3) 氨基丙基化，由于S-腺苷-L-甲硫氨酸在多胺合成中起重要作用，这些多胺最终会形成并循环利用蛋氨酸。有研究显示，在使用人关节软骨细胞进行的体外实验中，S-腺苷-L-甲硫氨酸可以促进蛋白聚糖合成和兔细胞增殖率。

体内研究

缺乏蛋氨酸腺苷转移酶1a (Mat1a) 的小鼠肝内S-腺苷-L-甲硫氨酸水平降低，并表现出氧化应激、脂肪性肝炎和肝细胞癌 (HCC)。然而，肝脏中S-腺苷-L-甲硫氨酸的高水平长期存在也会导致损伤和HCC的发生。因此，维持正常的肝内S-腺苷-L-甲硫氨酸水平对于维护肝脏健康并防止损伤和HCC至关重要。

文献信息

• Liquid filled delivery system, preferably an HPMC capsule filled with glycerol
  申请人：Warner-Lambert Company LLC

  公开号：EP1762232A1

  公开（公告）日：2007-03-14

  The present invention provides a delivery system comprising: (a) a container which is a formed body obtained from a film forming composition comprising at least one polysaccharide or polysaccharide derivative; (b) a liquid fill comprising a matrix composition of at least one solvent which is both polar and hygroscopic or a mixture of solvents each of which is both polar and hygroscopic; and (c) an active agent or a mixture of active agents wherein the active agent is soluble in said polar and hygroscopic solvent or mixture of polar and hygroscopic solvents, and a process for the preparation of said delivery system. Preferably the delivery system is a HPMC capsule filled with a matrix composition comprising glycerol and an active agent such as L-carnitine.

  本发明提供了一种递送系统，包括(a) 由至少一种多糖或多糖衍生物组成的成膜组合物形成的容器体；(b) 液体填充物，包括至少一种既有极性又有吸湿性的溶剂或每种溶剂都有极性又有吸湿性的溶剂混合物组成的基质组合物；(c) 活性剂或活性剂混合物，其中活性剂可溶于所述极性和吸湿性溶剂或极性和吸湿性溶剂混合物，以及制备所述给药系统的工艺。 该给药系统最好是填充有基质组合物的 HPMC 胶囊，基质组合物包括甘油和活性剂（如左旋肉碱）。
• Effervescent tablets and mouth-soluble granulates of S-adenosyl methionine and process for the preparation thereof
  申请人：Gnosis S.p.A.

  公开号：EP2189154A1

  公开（公告）日：2010-05-26

  A pharmaceutical or nutraceutical composition in form of effervescent tablets or mouth-soluble granulates comprising SAMe, an acid, a carbon dioxide source, calcium oxide and optionally pharmaceutically acceptable excipients.

  一种泡腾片或口服颗粒形式的药物或营养保健品组合物，由 SAMe、酸、二氧化碳源、氧化钙和可选的药学上可接受的赋形剂组成。
• Biomedically active and delivery site specific capsule-in-capsule liver supplement apparatus and method of use thereof
  申请人：Perry Bruce

  公开号：US10172801B1

  公开（公告）日：2019-01-08

  The invention comprises a biomedically active/delivery site specific capsule-in-capsule liver supplement and method of use thereof. A first set of constituents, of an outer capsule, of a capsule-in-capsule liver supplement, comprises one or more of choline and phosphatidylcholine; a second set of constituents, of an inner capsule, comprise one or more of methionine, glycyrrhetinic acid, silymarin, and phosphatidylcholine; and either capsule optionally contains one or more liver aiding/regulating natural products, where the outer capsule dissolves in the stomach and the inner capsule dissolves in the small intestine. Thus, the dual dissolution process in controlled environments results in complementary and synergistic delivery of liver regulating molecules in a bioavailable form ready for transport through the wall of the small intestine. Further, constituents of the capsule-in-capsule liver supplement include multiple inputs into the methionine cycle, which facilitates/synergistically aids the body's use of the methionine cycle, such as in liver regulation.

  本发明包括一种具有生物医学活性/给药部位特异性的胶囊包胶囊肝脏补充剂及其使用方法。胶囊包胶囊肝脏补充剂外层胶囊的第一组成分包括胆碱和磷脂酰胆碱中的一种或多种；内层胶囊的第二组成分包括蛋氨酸、甘草亭酸、水飞蓟素和磷脂酰胆碱中的一种或多种；任一胶囊均可选择含有一种或多种肝脏辅助/调节天然产物，其中外层胶囊在胃中溶解，内层胶囊在小肠中溶解。因此，在可控环境中的双重溶解过程可使肝脏调节分子以生物可利用的形式通过小肠壁运输，从而实现互补和协同作用。此外，"胶囊中的胶囊 "肝脏补充剂的成分包括对蛋氨酸循环的多种输入，从而促进/协同帮助人体利用蛋氨酸循环，如肝脏调节。
• Solid oral compositions based on S-adenosyl methionine and/or NADH and process for obtaining them
  申请人：GNOSIS SPA

  公开号：US10471088B2

  公开（公告）日：2019-11-12

  This invention relates to solid oral compositions based on SAMe and/or NADH or their salts in association with calcium oxide and/or calcium hydroxide and a process for obtaining them. This invention also relates to a method for stabilising a solid oral composition based on SAMe and/or NADH or their salts, making use of calcium oxide, calcium hydroxide optionally in association with malic acid, glutamic acid, xylitol, calcium sulphate hemihydrate, magnesium oxide and/or mixtures thereof. This invention also relates to the use of SAMe or its salts in association with calcium oxide and/or calcium hydroxide with the possible further addition of melatonin and/or 1-theanine and/or 1-tryptophan and/or 5-hydroxytryptophan for the treatment of depressive states.

  本发明涉及以 SAMe 和/或 NADH 或其盐为基础、与氧化钙和/或氢氧化钙结合的固体口服组合物，以及获得这些组合物的工艺。 本发明还涉及一种稳定基于 SAMe 和/或 NADH 或其盐类的固体口服组合物的方法，该方法利用氧化钙、氢氧化钙（可选择与苹果酸、谷氨酸、木糖醇、半水合硫酸钙、氧化镁和/或其混合物结合使用）。 本发明还涉及将 SAMe 或其盐与氧化钙和/或氢氧化钙结合使用，并可能进一步添加褪黑素和/或 1-茶氨酸和/或 1-色氨酸和/或 5-羟色氨酸，用于治疗抑郁状态。
• Stable compositions of S-adenosyl-l-methionine with dextran
  申请人：——

  公开号：US20030144244A1

  公开（公告）日：2003-07-31

  Stable compositions of S-adenosyl-l-methionine with dextran are described. The compositions according to the invention are stable over time and are valuable for use as active constituents in pharmaceutical and cosmeceutical preparations.

  本发明描述了 S-腺苷-l-蛋氨酸与葡聚糖的稳定组合物。本发明的组合物具有长期稳定性，可用作药物和化妆品制剂中的活性成分。